BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 22187055)

  • 1. The presence of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor on patients with rheumatoid arthritis (RA) does not interfere with the chance of clinical remission in a follow-up of 3 years.
    da Mota LM; Dos Santos Neto LL; de Carvalho JF; Pereira IA; Burlingame R; Ménard HA; Laurindo IM
    Rheumatol Int; 2012 Dec; 32(12):3807-12. PubMed ID: 22187055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibodies in early rheumatoid arthritis: Brasília cohort: results of a three-year serial analysis.
    da Mota LM; Santos Neto LL; Pereira IA; Burlingame R; Ménard HA; Laurindo IM
    Rev Bras Reumatol; 2011 Dec; 51(6):564-71. PubMed ID: 22124591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between rheumatoid factor isotypes and IgG anti-cyclic citrullinated peptide antibodies.
    Jaskowski TD; Hill HR; Russo KL; Lakos G; Szekanecz Z; Teodorescu M
    J Rheumatol; 2010 Aug; 37(8):1582-8. PubMed ID: 20516016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA.
    Agrawal S; Misra R; Aggarwal A
    Clin Rheumatol; 2007 Feb; 26(2):201-4. PubMed ID: 16572283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope.
    Lakos G; Soós L; Fekete A; Szabó Z; Zeher M; Horváth IF; Dankó K; Kapitány A; Gyetvai A; Szegedi G; Szekanecz Z
    Clin Exp Rheumatol; 2008; 26(2):253-60. PubMed ID: 18565246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
    Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
    J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disability and quality-of-life are not influenced by the prevalence of autoantibodies in early rheumatoid arthritis patients--results of the Brasília Cohort.
    Mota LM; Santos Neto LL; Burlingame RW; Ménard HA; Pereira IA; Carvalho JF; Laurindo IM
    Rev Bras Reumatol; 2012 Dec; 52(6):824-9. PubMed ID: 23223694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients.
    Derganova O; Martinez-Gamboa L; Egerer K; Bang H; Fredenhagen G; Roggenbuck D; Esaulenko I; Burmester GR; Chernykh T; Feist E
    Clin Exp Rheumatol; 2014; 32(5):622-9. PubMed ID: 25189876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Comprehensive Evaluation of the Relationship Between Different IgG and IgA Anti-Modified Protein Autoantibodies in Rheumatoid Arthritis.
    Grönwall C; Liljefors L; Bang H; Hensvold AH; Hansson M; Mathsson-Alm L; Israelsson L; Joshua V; Svärd A; Stålesen R; Titcombe PJ; Steen J; Piccoli L; Sherina N; Clavel C; Svenungsson E; Gunnarsson I; Saevarsdottir S; Kastbom A; Serre G; Alfredsson L; Malmström V; Rönnelid J; Catrina AI; Lundberg K; Klareskog L
    Front Immunol; 2021; 12():627986. PubMed ID: 34093522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis.
    Maraina CH; Nurdayana AK; Rusni D; Azwany Y
    Int J Rheum Dis; 2010 Oct; 13(4):335-9. PubMed ID: 21199468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis.
    Ateş A; Karaaslan Y; Aksaray S
    Clin Rheumatol; 2007 Apr; 26(4):499-504. PubMed ID: 16670828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset.
    Berglin E; Johansson T; Sundin U; Jidell E; Wadell G; Hallmans G; Rantapää-Dahlqvist S
    Ann Rheum Dis; 2006 Apr; 65(4):453-8. PubMed ID: 16176994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbamylated vimentin represents a relevant autoantigen in Latin American (Cuban) rheumatoid arthritis patients.
    Martínez G; Gómez JA; Bang H; Martínez-Gamboa L; Roggenbuck D; Burmester GR; Torres B; Prada D; Feist E
    Rheumatol Int; 2016 Jun; 36(6):781-91. PubMed ID: 27038800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence of autoantibodies in "seronegative" rheumatoid arthritis associates with classical risk factors and high disease activity.
    Reed E; Hedström AK; Hansson M; Mathsson-Alm L; Brynedal B; Saevarsdottir S; Cornillet M; Jakobsson PJ; Holmdahl R; Skriner K; Serre G; Alfredsson L; Rönnelid J; Lundberg K
    Arthritis Res Ther; 2020 Jul; 22(1):170. PubMed ID: 32678001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis.
    Kokkonen H; Mullazehi M; Berglin E; Hallmans G; Wadell G; Rönnelid J; Rantapää-Dahlqvist S
    Arthritis Res Ther; 2011 Feb; 13(1):R13. PubMed ID: 21291540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis.
    Bas S; Genevay S; Meyer O; Gabay C
    Rheumatology (Oxford); 2003 May; 42(5):677-80. PubMed ID: 12709545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis.
    Barouta G; Katsiari CG; Alexiou I; Liaskos C; Varna A; Bogdanos DP; Germenis AE; Sakkas LI
    Clin Rheumatol; 2017 Apr; 36(4):885-894. PubMed ID: 27943044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
    Soós L; Szekanecz Z; Szabó Z; Fekete A; Zeher M; Horváth IF; Dankó K; Kapitány A; Végvári A; Sipka S; Szegedi G; Lakos G
    J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.
    Rantapää-Dahlqvist S; de Jong BA; Berglin E; Hallmans G; Wadell G; Stenlund H; Sundin U; van Venrooij WJ
    Arthritis Rheum; 2003 Oct; 48(10):2741-9. PubMed ID: 14558078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.